Literature DB >> 12093137

Frameless stereotaxy as an alternative to fluoroscopy for transsphenoidal surgery: use of the InstaTrak-3000 and a novel headset.

David G Walker1, Chima Ohaegbulam, Peter McL Black.   

Abstract

Our aim was to evaluate the applicability of an electromagnetic-based frameless stereotactic system for use in transsphenoidal surgery. The system utilizes a novel headset that acts as a replaceable fiducial frame as well as a fixation point for the system's transmitter. It can replace the fluoroscope as a guide to navigation in the sphenoid sinus and sella. The system was used in a consecutive series of 11 patients undergoing transsphenoidal surgery. It was used in conjunction with intraoperative fluoroscopy. We found the Instatrak-3000 to correlate well with lateral fluoroscopic images, and provide additional information in the axial and coronal planes. The InstaTrak-3000 frameless stereotactic system is accurate and obviates the need for intraoperative fluoroscopy during transsphenoidal surgery. Compared to other frameless systems, it avoids the use of fiducial skin markers and head fixation. In common with other frameless stereotactic systems, it provides additional information important for safely approaching the sella and avoids intraoperative radiation exposure for the patient and operating room staff. Copyright 2002 Published by Elsevier Science Ltd.

Entities:  

Mesh:

Year:  2002        PMID: 12093137     DOI: 10.1054/jocn.2001.0964

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  2 in total

Review 1.  Intraoperative magnetic resonance imaging during surgery for pituitary adenomas: pros and cons.

Authors:  Michael Buchfelder; Sven-Martin Schlaffer
Journal:  Endocrine       Date:  2012-07-26       Impact factor: 3.633

2.  Prospects and limitations of different registration modalities in electromagnetic ENT navigation.

Authors:  Eric Soteriou; Juergen Grauvogel; Roland Laszig; Tanja Daniela Grauvogel
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-05-05       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.